Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06107010

Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Subacute Phase (Month 1 to 4)

Led by Wandercraft · Updated on 2025-02-04

66

Participants Needed

5

Research Sites

141 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The present clinical investigation - EarlyExo, is an interventional, international, multicentric, prospective, single-blinded randomized controlled trial. This clinical investigation is designed to test the hypothesis that early and intense introduction of walking sessions assisted by the Atalante exoskeleton, in a sample of hemiparetic patients with still non or poor ambulatory capacities (FAC 0 or 1) between one- and four-months post stroke, would result in a better recovery of functional walking compared to a control group only receiving conventional therapy. Improved recovery will be measured through the proportion of patients reaching a FAC score of 4 or higher at the end of the intervention period. The tested hypothesis is that this proportion will be higher in the Exo group. The duration of the intervention period in both groups is 6 weeks. * For the Exo group: 3 sessions per week (i.e., 18 one-hour sessions) with the Atalante device and 2 sessions per week (i.e., 12 one-hour sessions) of conventional therapy. * For the Control group: 5 sessions per week of conventional therapy (i.e., 30 one-hour sessions). The study will include 66 patients (33 in each arm) and takes place in two French centers, two German centers and one Spanish center.

CONDITIONS

Official Title

Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Subacute Phase (Month 1 to 4)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • >18 years old
  • First clinically significant disability due to stroke
  • Hemiparesis in acute-subacute phase (1 to 4 months since lesion) due to a stroke
  • Functional Ambulation Category score (FAC) <2
  • Patient with health insurance
  • Informed and willing to sign an informed consent form approved by the Ethics Committee. For clarity, if a motor impairment prevents the subject from signing by himself, he/she can still be included if the signature can be done by an impartial witness.
Not Eligible

You will not qualify if you...

  • Muscle overactivity in hip adductors, hamstrings, quadriceps and plantar flexors, which interferes with exoskeleton use, based on clinician investigator's opinion
  • Recent fracture (< 3 months) or any therapy inducing secondary osteoporosis
  • Excessive joint mechanical pain in the lower limbs based on clinician investigator's opinion
  • Pressure sore grade I or more over contact zones with Atalante system, according to the International Pressure Ulcer Classification System NPUAP - EPUA
  • Medical contra-indication to medium intensity physical strain
  • Orthostatic hypotension (loss of > 20 mmHg systolic BP after 3 minutes in standing position)
  • Uncontrolled seizures
  • Morphological contra-indications to the use of Atalante (as per user's manual)
  • Pregnant woman
  • Adults who lack the capacity to provide informed consent, and all those persons deprived of their liberty in prisons or other places of detention
  • Concurrent participation in another interventional trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Hôpitaux Universitaires Henri Mondor APHP, site Albert Chenevier

Créteil, France

Actively Recruiting

2

Centre de Médecine Physique et de Réadaptation APAJH de Pionsat

Pionsat, France

Actively Recruiting

3

Schön Klinik

Bad Aibling, Germany

Not Yet Recruiting

4

Vivantes Klinikum Spandau

Berlin, Germany

Actively Recruiting

5

Institut Guttmann

Barcelona, Spain

Actively Recruiting

Loading map...

Research Team

D

Dr Rebecca Sauvagnac, MD

CONTACT

L

Laure Bouché

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here